(ACHC) Acadia Healthcare - Overview
Sector: HealthcareIndustry: Medical Care Facilities | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.092m | Total Return -23.9% in 12m
Stock: Mental Health, Addiction Treatment, Residential Care, Outpatient Services
Total Rating 32
Risk 41
Buy Signal -0.68
| Risk 5d forecast | |
|---|---|
| Volatility | 69.4% |
| Relative Tail Risk | -12.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -34.01 |
| Character TTM | |
|---|---|
| Beta | 0.819 |
| Beta Downside | 0.181 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.63% |
| CAGR/Max DD | -0.37 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: ACHC Acadia Healthcare March 04, 2026
Acadia Healthcare Company, Inc. (ACHC) provides behavioral healthcare services across the United States and Puerto Rico. The company operates a variety of facilities, including acute inpatient psychiatric facilities, residential recovery facilities, eating disorder facilities, and outpatient centers. This business model focuses on diverse care settings to address various behavioral health and recovery needs.
The behavioral healthcare sector is experiencing increasing demand due to rising awareness and destigmatization of mental health conditions. ACHCs operations in this space position it within the Health Care Facilities sub-industry, a segment characterized by specialized medical infrastructure and services.
To further investigate ACHCs market position and financial performance, consider exploring detailed analytics on ValueRay.
Headlines to watch out for
- Inpatient psychiatric admissions drive revenue growth
- Staffing shortages increase labor costs
- Government reimbursement rates impact profitability
- Expansion of treatment facilities boosts market share
- Regulatory changes in behavioral health pose risk
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA 1.45 > 1.0 |
| NWC/Revenue: 8.72% < 20% (prev -0.01%; Δ 8.74% < -1%) |
| CFO/TA 0.02 > 3% & CFO 131.9m > Net Income -1.10b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.4m) vs 12m ago -1.68% < -2% |
| Gross Margin: 60.64% > 18% (prev 0.60%; Δ 6.00k% > 0.5%) |
| Asset Turnover: 57.69% > 50% (prev 52.95%; Δ 4.75% > 0%) |
| Interest Coverage Ratio: -6.68 > 6 (EBITDA TTM -736.8m / Interest Expense TTM 138.9m) |
Altman Z'' -1.43
| A: 0.05 (Total Current Assets 814.1m - Total Current Liabilities 525.2m) / Total Assets 5.53b |
| B: -0.14 (Retained Earnings -765.8m / Total Assets 5.53b) |
| C: -0.16 (EBIT TTM -927.1m / Avg Total Assets 5.74b) |
| D: -0.23 (Book Value of Equity -764.9m / Total Liabilities 3.39b) |
| Altman-Z'' Score: -1.43 = CCC |
Beneish M -3.24
| DSRI: 1.23 (Receivables 545.2m/422.0m, Revenue 3.31b/3.15b) |
| GMI: 0.99 (GM 60.64% / 60.15%) |
| AQI: 0.66 (AQ_t 0.27 / AQ_t-1 0.40) |
| SGI: 1.05 (Revenue 3.31b / 3.15b) |
| TATA: -0.22 (NI -1.10b - CFO 131.9m) / TA 5.53b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of ACHC shares?
As of March 28, 2026, the stock is trading at USD 22.91 with a total of 3,273,415 shares traded.
Over the past week, the price has changed by +0.79%, over one month by -2.26%, over three months by +58.00% and over the past year by -23.94%.
Over the past week, the price has changed by +0.79%, over one month by -2.26%, over three months by +58.00% and over the past year by -23.94%.
Is ACHC a buy, sell or hold?
Acadia Healthcare has received a consensus analysts rating of 4.36.
Therefore, it is recommended to buy ACHC.
- StrongBuy: 9
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.7 | -0.9% |
| Analysts Target Price | 22.7 | -0.9% |
ACHC Fundamental Data Overview March 25, 2026
P/E Forward = 15.9744
P/S = 0.6316
P/B = 1.0967
P/EG = 1.3745
Revenue TTM = 3.31b USD
EBIT TTM = -927.1m USD
EBITDA TTM = -736.8m USD
Long Term Debt = 2.47b USD (from longTermDebt, last quarter)
Short Term Debt = 50.7m USD (from shortTermDebt, last quarter)
Debt = 2.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.52b USD (from netDebt column, last quarter)
Enterprise Value = 4.61b USD (2.09b + Debt 2.65b - CCE 133.2m)
Interest Coverage Ratio = -6.68 (Ebit TTM -927.1m / Interest Expense TTM 138.9m)
EV/FCF = -10.49x (Enterprise Value 4.61b / FCF TTM -439.9m)
FCF Yield = -9.53% (FCF TTM -439.9m / Enterprise Value 4.61b)
FCF Margin = -13.28% (FCF TTM -439.9m / Revenue TTM 3.31b)
Net Margin = -33.29% (Net Income TTM -1.10b / Revenue TTM 3.31b)
Gross Margin = 60.64% ((Revenue TTM 3.31b - Cost of Revenue TTM 1.30b) / Revenue TTM)
Gross Margin QoQ = 11.68% (prev none%)
Tobins Q-Ratio = 0.83 (Enterprise Value 4.61b / Total Assets 5.53b)
Interest Expense / Debt = 1.43% (Interest Expense 37.9m / Debt 2.65b)
Taxrate = 21.0% (US default 21%)
NOPAT = -732.4m (EBIT -927.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 814.1m / Total Current Liabilities 525.2m)
Debt / Equity = 1.36 (Debt 2.65b / totalStockholderEquity, last quarter 1.95b)
Debt / EBITDA = -3.42 (negative EBITDA) (Net Debt 2.52b / EBITDA -736.8m)
Debt / FCF = -5.73 (negative FCF - burning cash) (Net Debt 2.52b / FCF TTM -439.9m)
Total Stockholder Equity = 2.80b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.20% (Net Income -1.10b / Total Assets 5.53b)
RoE = -39.42% (Net Income TTM -1.10b / Total Stockholder Equity 2.80b)
RoCE = -17.60% (EBIT -927.1m / Capital Employed (Equity 2.80b + L.T.Debt 2.47b))
RoIC = -14.31% (negative operating profit) (NOPAT -732.4m / Invested Capital 5.12b)
WACC = 4.54% (E(2.09b)/V(4.75b) * Re(8.86%) + D(2.65b)/V(4.75b) * Rd(1.43%) * (1-Tc(0.21)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.78%
[DCF] Fair Price = unknown (Cash Flow -439.9m)
EPS Correlation: -51.70 | EPS CAGR: -45.25% | SUE: -0.54 | # QB: 0
Revenue Correlation: 94.24 | Revenue CAGR: 7.95% | SUE: 1.68 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.46 | Chg7d=+0.000 | Chg30d=-0.184 | Revisions Net=-8 | Analysts=13
EPS current Year (2026-12-31): EPS=1.47 | Chg7d=+0.000 | Chg30d=-0.268 | Revisions Net=-7 | Growth EPS=-26.3% | Growth Revenue=+3.0%
EPS next Year (2027-12-31): EPS=1.68 | Chg7d=+0.000 | Chg30d=-0.272 | Revisions Net=-4 | Growth EPS=+13.8% | Growth Revenue=+5.8%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
P/S = 0.6316
P/B = 1.0967
P/EG = 1.3745
Revenue TTM = 3.31b USD
EBIT TTM = -927.1m USD
EBITDA TTM = -736.8m USD
Long Term Debt = 2.47b USD (from longTermDebt, last quarter)
Short Term Debt = 50.7m USD (from shortTermDebt, last quarter)
Debt = 2.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.52b USD (from netDebt column, last quarter)
Enterprise Value = 4.61b USD (2.09b + Debt 2.65b - CCE 133.2m)
Interest Coverage Ratio = -6.68 (Ebit TTM -927.1m / Interest Expense TTM 138.9m)
EV/FCF = -10.49x (Enterprise Value 4.61b / FCF TTM -439.9m)
FCF Yield = -9.53% (FCF TTM -439.9m / Enterprise Value 4.61b)
FCF Margin = -13.28% (FCF TTM -439.9m / Revenue TTM 3.31b)
Net Margin = -33.29% (Net Income TTM -1.10b / Revenue TTM 3.31b)
Gross Margin = 60.64% ((Revenue TTM 3.31b - Cost of Revenue TTM 1.30b) / Revenue TTM)
Gross Margin QoQ = 11.68% (prev none%)
Tobins Q-Ratio = 0.83 (Enterprise Value 4.61b / Total Assets 5.53b)
Interest Expense / Debt = 1.43% (Interest Expense 37.9m / Debt 2.65b)
Taxrate = 21.0% (US default 21%)
NOPAT = -732.4m (EBIT -927.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 814.1m / Total Current Liabilities 525.2m)
Debt / Equity = 1.36 (Debt 2.65b / totalStockholderEquity, last quarter 1.95b)
Debt / EBITDA = -3.42 (negative EBITDA) (Net Debt 2.52b / EBITDA -736.8m)
Debt / FCF = -5.73 (negative FCF - burning cash) (Net Debt 2.52b / FCF TTM -439.9m)
Total Stockholder Equity = 2.80b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.20% (Net Income -1.10b / Total Assets 5.53b)
RoE = -39.42% (Net Income TTM -1.10b / Total Stockholder Equity 2.80b)
RoCE = -17.60% (EBIT -927.1m / Capital Employed (Equity 2.80b + L.T.Debt 2.47b))
RoIC = -14.31% (negative operating profit) (NOPAT -732.4m / Invested Capital 5.12b)
WACC = 4.54% (E(2.09b)/V(4.75b) * Re(8.86%) + D(2.65b)/V(4.75b) * Rd(1.43%) * (1-Tc(0.21)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.78%
[DCF] Fair Price = unknown (Cash Flow -439.9m)
EPS Correlation: -51.70 | EPS CAGR: -45.25% | SUE: -0.54 | # QB: 0
Revenue Correlation: 94.24 | Revenue CAGR: 7.95% | SUE: 1.68 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.46 | Chg7d=+0.000 | Chg30d=-0.184 | Revisions Net=-8 | Analysts=13
EPS current Year (2026-12-31): EPS=1.47 | Chg7d=+0.000 | Chg30d=-0.268 | Revisions Net=-7 | Growth EPS=-26.3% | Growth Revenue=+3.0%
EPS next Year (2027-12-31): EPS=1.68 | Chg7d=+0.000 | Chg30d=-0.272 | Revisions Net=-4 | Growth EPS=+13.8% | Growth Revenue=+5.8%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)